Evidence map›Paper›PMID 41948466›Full record

ArticleTherapeutic advances in medical oncology2026

S100A4 characterize antigen-presenting cancer-associated fibroblasts and predicts surgical outcomes in relapsed ovarian cancer.

Yilizhati Maimaiti, Yulian Chen, Longxia Li, Meichun Cai, Zeyun Li, Lifeng Lin, Shangbing Gao, Guanglei Zhuang, Wei Wu, Rongyu Zang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yilizhati MaimaitiDepartment of Gynecologic Oncology, Cancer Center, Institute for Ovarian Cancer, Fudan University Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0009-0003-2348-9267
Yulian ChenDepartment of Gynecologic Oncology, Cancer Center, Institute for Ovarian Cancer, Fudan University Zhongshan Hospital, Fudan University, Shanghai, China.
Longxia LiDepartment of Gynecologic Oncology, Cancer Center, Institute for Ovarian Cancer, Fudan University Zhongshan Hospital, Fudan University, Shanghai, China.
Meichun CaiShanghai Key Laboratory of Gynecologic Oncology, School of Medicine, Ren Ji Hospital, Shanghai Jiao Tong University, Shanghai, China.
Zeyun LiDepartment of Gynecologic Oncology, Cancer Center, Institute for Ovarian Cancer, Fudan University Zhongshan Hospital, Fudan University, Shanghai, China.
Lifeng LinDepartment of Gynecologic Oncology, Cancer Center, Institute for Ovarian Cancer, Fudan University Zhongshan Hospital, Fudan University, Shanghai, China.
Shangbing GaoDepartment of Gynecologic Oncology, Cancer Center, Institute for Ovarian Cancer, Fudan University Zhongshan Hospital, Fudan University, Shanghai, China.
Guanglei ZhuangShanghai Key Laboratory of Gynecologic Oncology, School of Medicine, Ren Ji Hospital, Shanghai Jiao Tong University, Shanghai, China.
Wei WuDepartment of Gynecologic Oncology, Cancer Center, Institute for Ovarian Cancer, Fudan University Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Rongyu ZangDepartment of Gynecologic Oncology, Cancer Center, Institute for Ovarian Cancer, Fudan University Zhongshan Hospital, Fudan University, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Relapsed ovarian cancer (ROC) presents significant therapeutic challenges, and complete resection during secondary cytoreductive surgery (SCR) has been associated with improved survival. However, the contribution of the tumor microenvironment (TME), particularly cancer-associated fibroblasts (CAFs), to surgical outcomes remains unclear. Objectives: This study aimed to characterize CAFs heterogeneity in ROC and identify specific CAF subsets associated with immune modulation and surgical prognosis. Design: A multi-platform integrative study combining spatial, single-cell, and transcriptomic analyses to investigate CAF phenotypes and their clinical relevance in ROC. Methods: Multiplex immunohistochemistry and spatial digital phenotyping were performed on 31 ROC samples. Single-cell RNA sequencing (scRNA-seq) was conducted on 11 tumors to define CAF clusters. Transcriptomic meta-analysis across multiple external datasets was used to evaluate prognostic significance. Spatial relationships between CAF subsets and immune cells were analyzed, and antigen-presenting CAF signatures were assessed based on marker co-expression patterns. Results: We identified a predominant S100A4 Conclusion: This study identifies S100A4

Indexed as

cancer-associated fibroblastsprognostic biomarkersrelapsed ovarian cancer

Identifiers

PMID41948466
PMCPMC13051167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.